Robert L Ferris Selected Research

Cetuximab (Erbitux)

1/2022	Phase I Trial of Cetuximab, Radiotherapy, and Ipilimumab in Locally Advanced Head and Neck Cancer.
8/2021	Epidermal Growth Factor Receptor-Targeted Therapy for Head and Neck Cancer.
6/2020	Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer.
12/2019	Immunotherapy for head and neck cancer: Recent advances and future directions.
1/2019	Circulating exosomes measure responses to therapy in head and neck cancer patients treated with cetuximab, ipilimumab, and IMRT.
1/2019	Immunogenomic correlates of response to cetuximab monotherapy in head and neck squamous cell carcinoma.
1/2019	Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use.
12/2018	PD-L1 Mediates Dysfunction in Activated PD-1+ NK Cells in Head and Neck Cancer Patients.
11/2018	Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial.
2/2018	Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Robert L Ferris Research Topics

Disease

180	Neoplasms (Cancer) 10/2022 - 11/2003
124	Squamous Cell Carcinoma of Head and Neck 01/2022 - 03/2004
90	Head and Neck Neoplasms (Head and Neck Cancer) 01/2022 - 01/2004
19	Neoplasm Metastasis (Metastasis) 01/2017 - 03/2004
13	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2022 - 12/2004
13	Carcinogenesis 01/2021 - 03/2005
10	Thyroid Neoplasms (Thyroid Cancer) 05/2022 - 09/2007
8	Melanoma (Melanoma, Malignant) 01/2022 - 01/2017
8	Disease Progression 10/2020 - 01/2005
8	Carcinoma (Carcinomatosis) 11/2016 - 04/2005
7	Oropharyngeal Neoplasms 10/2022 - 12/2004
5	Deglutition Disorders (Dysphagia) 10/2022 - 01/2010
5	Inflammation (Inflammations) 12/2021 - 01/2006
5	Hemorrhage 01/2021 - 01/2016
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 08/2014
4	Infections 01/2021 - 10/2004
4	Squamous Cell Neoplasms (Squamous Cell Cancer) 12/2018 - 09/2014
4	Pemphigus (Pemphigus Vulgaris) 08/2013 - 03/2005
3	Colorectal Neoplasms (Colorectal Cancer) 01/2021 - 08/2011
3	Hypoxia (Hypoxemia) 01/2021 - 01/2014
3	Bites and Stings (Sting) 01/2020 - 01/2018
3	Margins of Excision 01/2018 - 01/2016
3	Fatigue 10/2017 - 06/2005
3	Sarcoma (Soft Tissue Sarcoma) 04/2017 - 12/2014
2	Fever (Fevers) 06/2021 - 11/2018
2	Papillomavirus Infections 11/2019 - 10/2004

Drug/Important Bio-Agent (IBA)

43	Cetuximab (Erbitux)FDA Link 01/2022 - 12/2007
33	Biomarkers (Surrogate Marker)IBA 01/2022 - 03/2005
21	ErbB Receptors (EGF Receptor)IBA 08/2021 - 01/2007
20	Monoclonal AntibodiesIBA 08/2021 - 12/2007
20	Proteins (Proteins, Gene)FDA Link 01/2021 - 10/2004
15	NivolumabIBA 01/2022 - 11/2016
15	Neoplasm Antigens (Tumor Antigens)IBA 01/2018 - 10/2004
11	CytokinesIBA 01/2018 - 03/2005
10	PlatinumIBA 01/2022 - 11/2016
9	LigandsIBA 01/2022 - 03/2004
8	VaccinesIBA 01/2022 - 06/2007
8	Cisplatin (Platino)FDA LinkGeneric 06/2021 - 05/2010
8	Peptides (Polypeptides)IBA 07/2018 - 10/2004
8	AntigensIBA 08/2013 - 03/2005
7	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2018
7	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 04/2016
7	Biological ProductsIBA 10/2018 - 05/2009
7	Chemokine ReceptorsIBA 01/2012 - 03/2004
6	RNA (Ribonucleic Acid)IBA 12/2021 - 03/2014
6	AntibodiesIBA 12/2019 - 03/2008
6	EpitopesIBA 01/2019 - 11/2005
6	HLA Antigens (Human Leukocyte Antigens)IBA 01/2019 - 01/2005
6	Histocompatibility Antigens Class IIBA 01/2018 - 01/2005
6	ChemokinesIBA 01/2018 - 05/2005
6	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 04/2017 - 06/2005
5	CarcinogensIBA 01/2022 - 05/2008
5	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 10/2011
5	Indicators and Reagents (Reagents)IBA 01/2018 - 11/2009
4	pembrolizumabIBA 01/2022 - 01/2019
4	B7-H1 AntigenIBA 01/2022 - 03/2016
4	HLA-A*02:01 antigenIBA 07/2018 - 10/2004
4	Messenger RNA (mRNA)IBA 01/2018 - 05/2005
4	HLA-A Antigens (HLA-A)IBA 01/2018 - 12/2005
4	Docetaxel (Taxotere)FDA Link 01/2017 - 12/2010
4	Panitumumab (Vectibix)FDA Link 11/2016 - 12/2007
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2022 - 03/2014
3	Interleukin-6 (Interleukin 6)IBA 01/2022 - 10/2011
3	IpilimumabIBA 01/2022 - 10/2018
3	Pharmaceutical PreparationsIBA 01/2022 - 09/2015
3	Small Interfering RNA (siRNA)IBA 01/2021 - 11/2009
3	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 06/2020 - 10/2008
3	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2020 - 07/2005
3	VTX-2337IBA 11/2018 - 08/2013
3	Immunoglobulin G (IgG)IBA 02/2018 - 01/2015
3	Phosphotransferases (Kinase)IBA 01/2018 - 09/2005
3	InterferonsIBA 01/2018 - 09/2014
3	MicroRNAs (MicroRNA)IBA 04/2017 - 04/2011
3	MucinsIBA 03/2017 - 01/2016
3	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2017 - 11/2012
3	Growth Factor ReceptorsIBA 01/2017 - 03/2008
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 10/2016 - 06/2013
3	Codon (Codons)IBA 05/2015 - 10/2010
3	Tumor Biomarkers (Tumor Markers)IBA 01/2015 - 11/2009
3	Epidermal Growth Factor (EGF)IBA 10/2014 - 01/2007
3	CalciumIBA 08/2013 - 04/2011
2	SteroidsIBA 01/2022 - 11/2003
2	Neuropilin-1IBA 12/2021 - 01/2020
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2021 - 07/2014
2	Death Domain ReceptorsIBA 01/2021 - 03/2017
2	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2021 - 01/2019
2	Environmental CarcinogensIBA 01/2020 - 04/2016
2	Interferon Type IIBA 01/2020 - 01/2018
2	Fluorouracil (Carac)FDA LinkGeneric 12/2019 - 01/2019

Therapy/Procedure

79	Therapeutics 10/2022 - 11/2003
58	Immunotherapy 01/2022 - 01/2004
44	Radiotherapy 10/2022 - 04/2005
22	Drug Therapy (Chemotherapy) 01/2022 - 06/2005
15	Neck Dissection (Radical Neck Dissection) 01/2021 - 12/2004
9	Re-Irradiation 01/2019 - 04/2011
5	Chemoradiotherapy 01/2021 - 01/2010
4	Thyroidectomy 01/2018 - 11/2008
3	Neoadjuvant Therapy 01/2021 - 11/2012
3	Glossectomy 12/2017 - 11/2013
2	Aftercare (After-Treatment) 01/2020 - 01/2017